Summary by Moomoo AI
On April 1, 2024, Timothy Stover, the Vice President, Corporate Controller, and the principal financial officer and principal accounting officer of NexImmune, Inc., announced his resignation effective April 16, 2024. The company clarified that Stover's departure was not due to any disagreements regarding operations, policies, or practices. Subsequently, on April 5, 2024, NexImmune's Board of Directors appointed Albert N. Marchio II as the Interim Chief Financial Officer. Marchio, with a 32-year tenure in the pharmaceutical industry, will assume the role of principal financial officer and principal accounting officer following Stover's departure. His previous experience includes roles at Danforth Advisors LLC, Fresh Tracks Therapeutics, Inc., and Edge Therapeutics, Inc., among others. The company has a Consulting Agreement with Danforth Advisors, which provides various services including the interim CFO services to be rendered by Marchio. The agreement also includes indemnification provisions and compensation on an hourly rate basis for services provided.